Skip To Main Content
Intended for US Payers

Inflammation and immunology

Sanofi Market Access logo. Science. Innovation. Value.
Text callout highlighting “Our medicines: Immunology | Sanofi. Following the science to get inflammation under control and restore immune balance in many diseases.”

 

 

 

 

FDA-approved products: Therapy areas

Explore the proven efficacy and demonstrated safety profile across our portfolio of FDA-approved products targeting:

Illustration of inflammation around the shoulder joint.

Illustration of a T-cell representing immune system function.

Type 1 diabetes

Type 1 diabetes

Illustration of magnifying glass over immune cells to depict cellular inflammation.

 

 

 

Recent scientific advances have revealed that excessive type 2 inflammation—an overactive immune response—plays a key role in various atopic, allergic, and inflammatory diseases1-3

Graphic outlining the stages of immune-related inflammatory diseases.
Text callout highlighting “It is not uncommon for patients to have 2 or more type 2 inflammatory diseases, with different levels of severity. When a person has multiple coexisting type 2 inflammatory diseases, management is often more challenging.”

Exclusive, near-term disease spotlight for payers

Product information

 

 

 

 

 

Pipeline: Therapy areas

Exclusive, near-term disease spotlight for payers

This information is designed to support your early market access decisions.

Text callout highlighting “Discover unmet needs and potential treatment in:”

 

 

Illustration showing activated platelets involved in inflammation.

Immune thrombocytopenia

Disease state information

Illustration of a T-cell representing immune system function.

 

 

Explore our ongoing pipeline research investigating:

 

Skin disorders

Illustration of hands with visible symptoms of atopic dermatitis.

Atopic dermatitis

Study design 1

Study design 2

Study design 3

Study design 4

Study design 5

Study design 6

Study design 7

Illustration of an arm showing red, scaly skin affected by psoriasis.

Psoriasis

Study design

Illustration of a lichen simplex chronicus with thickened, itchy skin.

Lichen simplex chronicus

Study design 1

Study design 2

Illustration of a cross-section of skin showing hair loss due to alopecia.

Alopecia areata

Study design

Illustration of a unexplained chronic itching (CPUO) affecting the skin.

Chronic pruritus of unknown origin (CPUO)

Study design

Illustration of stiff, thickened skin on arms, indicative of scleroderma.

Scleroderma
 

Study design

Illustration of inflamed skin lesions in the armpit typical of hidradenitis suppurativa.

Hidradenitis suppurativa
 

Study design 1

Study design 2

Study design 3

Respiratory disorders

Illustration of a lung showing narrowed airways typical in asthma.

Asthma
 

Study design 1

Study design 2

Study design 3

Illustration showing damaged lungs and airflow limitation in COPD.

Chronic obstructive pulmonary disease

Study design 1

Study design 2

Study design 3

Illustration of dilated airways representing bronchiectasis.

Bronchiectasis
 

Study design

Illustration of nasal passage with polyps.

Chronic rhinosinusitis with nasal polyps

Study design 1

Study design 2

Study design 3

Illustration of nasal passage without polyps.

Chronic rhinosinusitis without nasal polyps

Study design

Gastrointestinal disorders

Illustration of digestive tract highlighting inflamed colon in ulcerative colitis.

Ulcerative colitis

Study design 1

Study design 2

Study design 3

Illustration of digestive tract with patchy inflammation showing Crohn’s disease.

Crohn’s disease

Study design 1

Study design 2

Illustration of stomach diagram indicating eosinophilic inflammation.

Eosinophilic gastritis

Study design

Illustration of intestinal showing celiac-related inflammation.

Celiac disease

Study design

Autoimmune and systemic diseases

Illustration of a woman with butterfly-shaped rash, characteristic of lupus.

Systemic lupus erythematosus

Study design

Illustration of a knee joint, showing damage from rheumatoid arthritis.

Rheumatoid arthritis

Study design

Illustration of IgG4 antibody associated with chronic inflammatory response.

IgG4-related disease

Study design

Illustration of immune cells targeting insulin-producing pancreatic cells.

Type 1 diabetes (T1D)

Study design

Transplant and rejection disorders

Illustration of Red blood cell and immune cells representing graft-versus-host disease.

Chronic graft-versus-host disease (GVHD)

Study design

Illustration of an antibody showing immune-mediated transplant rejection.

Antibody-mediated rejection
 

Study design

Illustration of a lung representing allograft rejection.

Chronic lung allogra dysfunction
 

Study design

 

 

 

 

 

Illustration of healthcare tools including a clipboard, syringe, and medication.

Explore more therapeutic areas of focus in our specialty care portfolio

Learn More

 

 

 

FDA, US Food and Drug Administration; IgG4, immunoglobulin G4.

 

References: 1. Gandhi NA, Bennett BL, Graham NMH, Pirozzi G, Stahl N, Yancopoulos GD. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15(1):35–50. doi:10.1038/nrd4624. 2. Carr S, Chan ES, Watson W. Eosinophilic esophagitis. Allergy Asthma Clin Immunol. 2018;14(suppl 2):58. doi:10.1186/s13223-018-0287-0. 3. Steinke JW, Wilson JM. Aspirin-exacerbated respiratory disease: pathophysiological insights and clinical advances. J Asthma Allergy. 2016;9:37–43. doi:10.2147/JAA.S88739. 4. Global Strategy for Asthma Management and Prevention, 2024. Global Initiative for Asthma. Updated 2024. Accessed May 3, 2025. https://ginasthma.org/wp-content/uploads/2024/05/GINA-2024-Strategy-Report-24_05_22_WMS.pdf. 5. Corren J. Role of interleukin-13 in asthma. Curr Allergy Asthma Rep. 2013;13(5):415–420. doi:10.1007/s11882-013-0373-9. 6. Gandhi NA, Pirozzi G, Graham NMH. Commonality of the IL-4/IL-13 pathway in atopic diseases. Expert Rev Clin Immunol. 2017;13(5):425–437. doi:10.1080/1744666X.2017.1298443. 7. Nair MG, Guild KJ, Artis D. Novel effector molecules in type 2 inflammation: lessons drawn from helminth infection and allergy. J Immunol. 2006;177(3):1393–1399. doi:10.4049/jimmunol.177.3.1393. 8. Webb LM, Tait Wojno ED. Notch signaling orchestrates helminth-induced type 2 inflammation. Trends Immunol. 2019;40(6):538–552. doi:10.1016/j.it.2019.04.003. 9. Philpott CM, Erskine S, Hopkins C, et al. Prevalence of asthma, aspirin sensitivity and allergy in chronic rhinosinusitis: data from the UK National Chronic Rhinosinusitis Epidemiology Study. Respir Res. 2018;19(1):129. doi:10.1186/s12931-018-0823-y. 10. Wen RK, Kim YC, Kang MG, et al. Age-related prevalence of chronic rhinosinusitis and nasal polyps and their relationships with asthma onset. Ann Allergy Asthma Immunol. 2018;120(4):389–394. doi:10.1016/j.anai.2018.02.005. 11. Simpson E, Guttman-Yassky E, Margolis DJ, et al. Chronicity, comorbidity and life course impairment in atopic dermatitis: insights from a cross-sectional study in US adults. Poster presented at: 25th European Academy of Dermatology and Venereology (EADV) Congress; September 28–October 2, 2016; Vienna, Austria. 12. Rudmik L, Soler ZM. Medical therapies for adult chronic sinusitis: a systematic review. JAMA. 2015;314(9):926–939. doi:10.1001/jama.2015.7544. 13. Rand CS, Wright RJ, Cabana MD, et al. Mediators of asthma outcomes. J Allergy Clin Immunol. 2012;129(3)(suppl):S136–S141. doi:10.1016/j.jaci.2011.12.987. 14. Stull DE, Roberts L, Frank L, Heithoff K. Relationship of nasal congestion with sleep, mood, and productivity. Curr Med Res Opin. 2007;23(4):811–819. doi:10.1185/030079907X178793. 15. Nordin S, Blomqvist EH, Olsson P, Stjärne P, Ehnhage A. Effects of smell loss on daily life and adopted coping strategies in patients with nasal polyposis with asthma. Acta Otolaryngol. 2011;131(8):826–832. doi:10.3109/00016489.2010.539625. 16. Iskedarjian M, Piwko C, Shear NH, Langley RGB, Einarson TR. Topical calcineurin inhibitors in the treatment of atopic dermatitis: a meta-analysis of clinical evidence. Am J Clin Dermatol. 2004;5(4):267–279. doi:10.2165/00128071-200405040-00006. 17. Martins JC, Martins C, Aoki V, Gois AFT, Ishii HA, da Silva EMK. Topical tacrolimus for atopic dermatitis. Cochrane Database Syst Rev. 2015;2015(7):CD009864. doi:10.1002/14651858.CD009864.pub2. 18. Meggitt SJ, Gray JC, Reynolds NJ. Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomized controlled trial. Lancet. 2006;367(9513):839–846. doi:10.1016/S0140-6736(06)68340-2.

This site is intended for US payers only.
© 2025 Sanofi. All rights reserved.